Corrigendum to “Beta blocker use and breast cancer survival by subtypes: A population-based cohort study” [The Breast 81 (2025) 104474]
Oliver William Scott, Sandar Tin Tin, Edoardo Botteri
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer, Stress, Anesthesia, and Immune Response
The authors regret to inform readers that we have identified three instances of the phrasing “molecular subtype” used in the first version of the published manuscript (two in Fig. 1 and one in Supplementary Table 4). As microassays or other sophisticated methods of determining ER, PR, and HER2 statuses are not routinely carried out in New Zealand, the biomarkers used to determine breast cancer subtypes do not reflect tests carried out on a molecular level. As such, we have removed the word “molecular” and exclusively used “subtype” instead.Image 1
The authors would like to apologise for any inconvenience caused.